New Search

Export article

Risks to the 340B Drug Pricing Program—Reply

Ryan P. Knox, Ameet Sarpatwari
Published: 20 September 2022
 in JAMA

Abstract:In Reply Pharmaceutical manufacturers have unilaterally adopted a range of policies concerning the delivery of 340B discounted drugs to contract pharmacies, from requiring that certain covered entities submit insurance claims data for 340B drugs dispensed at these locations to limiting the number of contract pharmacies a covered entity can engage. We believe that it is accurate to label the former policy, which imposes a limiting condition, as a restriction. We also believe, contrary to Dr Daifotis’ assertion, that the US District Court for the District of Columbia’s discussion of using insurance claims data “to implement the antifraud audit and dispute resolution provisions” of the 340B statute did not constitute an endorsement of the practice. The court explicitly noted that “[b]ecause the parties had not adequately argued their respective positions” on whether conditions were permitted under the 340B statute, it declined to rule on the issue.1 Of note, the US District Court for the District of New Jersey referred to a similar policy requiring the submission of insurance claims data as a restriction and held that the policy violated the 340B statute.2
Keywords: 340B / insurance claims data / pharmacies / Reply / contract / believe

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "JAMA" .
References (2)
    Back to Top Top